The global next-generation sequencing (NGS) market reached a value of US$ 13.82 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 40.25 Billion by 2027, exhibiting a CAGR of 19.5% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Next-generation sequencing, or high-throughput sequencing, refers to the process of determining the sequence of nucleotides in a section of the DNA. It includes procedures such as sequencing by synthesis (SBS), ion semiconductor sequencing, nanopore sequencing and single-molecule real-time (SMRT) sequencing. It is a cost-effective solution that offers precise results with high accuracy and speed. This enables the analysis of millions of DNA molecules simultaneously, which facilitates research in the fields of personalized and genetic medicines, agriculture and animal research, and clinical diagnostics.

Next-Generation Sequencing (NGS) Market Drivers:

The increasing prevalence of chronic medical ailments, such as cancer, along with various technological advancements in the field of medical sciences, is one of the key factors driving the growth of the market. Owing to the widespread adoption of liquid biopsies in cancer diagnostics, there has been a significant increase in the utilization of NGS technologies. These technologies utilize cell-free circulating tumor DNA (ctDNA) as a non-invasive cancer biomarker for real-time cancer monitoring and detection. Furthermore, the increasing adoption of genome mapping programs to predict the development of various diseases is also providing a boost to the market growth. Genetic maps are used for guiding scientists to analyze the genes that are responsible for increasing the prevalence of diabetes, heart diseases, asthma, cancer and psychiatric conditions. Additionally, various technological advancements and integration with the cloud-computing systems for improved data management, are creating a positive impact on the market growth. Other factors, including the declining costs of NGS systems and extensive research and development (R&D) activities in the field of sequencing chemistry, molecular biology and technical engineering, are projected to drive the global next-generation sequencing market further.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global next-generation sequencing (NGS) market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on sequencing type, product type, technology, application and end-user.

Breakup by Sequencing Type:

Whole Genome Sequencing
Targeted Resequencing
Whole Exome Sequencing
RNA Sequencing
CHIP Sequencing
De Novo Sequencing
Methyl Sequencing
Others

Breakup by Product Type:

Instruments
Reagents and Consumables
Software and Services

Breakup by Technology:

Sequencing by Synthesis
Ion Semiconductor Sequencing
Single-Molecule Real-Time Sequencing
Nanopore Sequencing
Others

Breakup by Application:

Biomarker and Cancer
Drug Discovery and Personalized Medicine
Genetic Screening
Diagnostics
Agriculture and Animal Research
Others

Breakup by End-User:

Academic Institutes & Research Centers
Hospitals & Clinics
Pharmaceutical & Biotechnology Companies
Others

Breakup by Region:

North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Agilent Technologies, Becton Dickinson and Company, 10x Genomics, BGI Group, Eurofins Scientific, F. Hoffmann-La Roche AG, Illumina Inc., Genewiz, Macrogen, Oxford Nanopore Technologies, Pacific Biosciences, PerkinElmer, Thermo Fisher Scientific, Qiagen N.V., GenapSys Inc., etc. Key Questions Answered in this Report
1. What is the expected growth rate of the global next-generation sequencing (NGS) market?
2. What has been the impact of COVID-19 on the global next-generation sequencing (NGS) market?
3. What are the key factors driving the global next-generation sequencing (NGS) market?
4. What is the breakup of the global next-generation sequencing (NGS) market based on the sequencing type?
5. What is the breakup of the global next-generation sequencing (NGS) market based on the product type?
6. What is the breakup of the global next-generation sequencing (NGS) market based on the technology?
7. What is the breakup of the global next-generation sequencing (NGS) market based on the end-user?
8. What is the breakup of the global next-generation sequencing (NGS) market based on the application?
9. What are the key regions in the global next-generation sequencing (NGS) market?
10. Who are the key players/companies in the global next-generation sequencing (NGS) market?